Rosario González

Abstract P2-07-08: Identification of UGT2B15 as a potential biomarker in response to neoadjuvant therapy in HER2+ breast cancer

Ana Gil-Torralvo, Marta Benavent, Maria A Dominguez-Cejudo, Alejandro Falcón et autres

Abstract INTRODUCTION. In response to neoadjuvant therapy, pathological complete response (pCR; lack of residual disease in breast and lymph nodes), has been proposed as a prognostic marker for long-term clinical outcomes, such as disease-free (DFS) and overall survival (OS), in human epidermal …

es (code pays fourni par la source)

Gene expression profiling involved in response to neoadjuvant therapy in breast cancer.

Salvador Bofill, Carmen Garrigós, Marta Benavent, Rosario González et autres

e12618 Background: Neoadjuvant systemic therapy for breast cancer is used increasingly but, there is a group of patients which do not benefit from this therapy. With these premises, we stablished that our main objective was to identify differential expression genes patterns in …

es (code pays fourni par la source)

CDK4/6 inhibitors beyond second line, is it worthy? A real-world data experience.

Alejandro Falcón, Javier Salvador Bofill, Álvaro Montaño, Marta Benavent et autres

e13033 Background: CDK4/6 inhibitors as Palbociclib, Ribociclib and Abemaciclib has become the first or second line in advanced or metastatic luminal breast cancer HER2 negative. We only have data about the use of Abemaciclib in monotherapy beyond second line. Methods: We have …

es (code pays fourni par la source)

Abstract P1-05-09: Role of long non coding RNAs in response to neoadjuvant therapy in triple negative and Her2+ subtypes breast cancer

Javier Salvador, Ana L. S. Gil, Marta Benavent, Sonia Molina‐Pinelo et autres

Abstract Background: Long non-coding RNAs (LncRNAs) are important regulators of gene expression, acting at almost all regulatory levels, both transcriptional and post-transcriptional. It has been described that LncRNAs have a relevant role both in biological processes and in the growth and progression …

es (code pays fourni par la source)

Biomarkers involved in the neoadjuvant therapy response in triple-negative and Her2+ subtypes breast cancer.

Salvador Bofill, Marta Benavent, Ana L. S. Gil, Antonia Pineda et autres

e12098 Background: Neoadjuvant systemic therapy for breast cancer is used increasingly for patients with breast cancer. One of the more compelling theoretical arguments for primary systemic therapy is its value as an in vivo test for drug sensitivity. The oncogenesis of breast …

es (code pays fourni par la source)

Circulating LncRNAs as predictive biomarkers by molecular subtypes in advanced breast tumors.

Javier Salvador, María Luisa Pecero, Ana L. S. Gil, María Rodríguez de la Borbolla et autres

e23041 Background: Breast cancer is the most common malignant tumor in women worldwide. The leading breast cancer deaths are due to advanced disease stage. For this reason, identification of novel breast cancer progression-associated biomarkers would enhance the clinical management of each patient. …

es (code pays fourni par la source)

Gastrosquisis inviable neonatal

Rosario González

es (code pays fourni par la source)

Protective Effect of Ischemic Preconditioning on Cold Preservation and Reperfusion Injury Associated With Rat Intestinal Transplantation

Anna Solà, Javier de, Rosario González, Neus Prats et autres

OBJECTIVE: To define the protective effect of ischemic preconditioning on cold ischemia and reperfusion injury associated with intestinal transplantation, and the role of nitric oxide in this process. SUMMARY BACKGROUND DATA: Ischemia/reperfusion injury continues to be a significant obstacle in small bowel …

es (code pays fourni par la source)